Assenagon Asset Management S.A. Raises Stock Position in Insulet Corporation $PODD

Assenagon Asset Management S.A. increased its stake in Insulet Corporation (NASDAQ:PODD) by 105.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 132,218 shares of the medical instruments supplier’s stock after acquiring an additional 67,772 shares during the period. Assenagon Asset Management S.A. owned approximately 0.19% of Insulet worth $40,820,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Oak Thistle LLC purchased a new stake in Insulet during the 3rd quarter valued at approximately $2,435,000. Gradient Investments LLC raised its stake in shares of Insulet by 5.8% during the third quarter. Gradient Investments LLC now owns 58,664 shares of the medical instruments supplier’s stock worth $18,111,000 after purchasing an additional 3,191 shares during the last quarter. Aaron Wealth Advisors LLC raised its stake in shares of Insulet by 139.2% during the third quarter. Aaron Wealth Advisors LLC now owns 2,213 shares of the medical instruments supplier’s stock worth $683,000 after purchasing an additional 1,288 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Insulet by 13.9% during the third quarter. GAMMA Investing LLC now owns 3,325 shares of the medical instruments supplier’s stock worth $1,027,000 after purchasing an additional 407 shares during the period. Finally, Praxis Investment Management Inc. grew its position in Insulet by 55.9% in the 3rd quarter. Praxis Investment Management Inc. now owns 2,588 shares of the medical instruments supplier’s stock valued at $799,000 after buying an additional 928 shares during the last quarter.

Analyst Upgrades and Downgrades

PODD has been the subject of a number of analyst reports. Royal Bank Of Canada increased their target price on Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Barclays increased their price objective on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 5th. BTIG Research boosted their target price on shares of Insulet from $370.00 to $380.00 and gave the stock a “buy” rating in a research report on Friday, November 21st. JPMorgan Chase & Co. upped their price target on shares of Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $379.00.

Insulet Stock Performance

Shares of NASDAQ:PODD opened at $292.88 on Friday. The business’s 50-day simple moving average is $316.92 and its 200 day simple moving average is $314.01. Insulet Corporation has a one year low of $230.05 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.18 and a current ratio of 2.87. The company has a market cap of $20.60 billion, a P/E ratio of 84.89, a PEG ratio of 2.04 and a beta of 1.37.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The business had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. During the same period last year, the business earned $1.08 EPS. The business’s revenue was up 29.9% on a year-over-year basis. On average, sell-side analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.